These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37435218)

  • 1. Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma.
    Lee HM; Alder L; Nguyen M; Dougherty SC; Qu Y; Thacker LR; Poklepovic A
    J Gastrointest Oncol; 2023 Jun; 14(3):1378-1391. PubMed ID: 37435218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
    Goswami P; Adeniran OR; K Frantz S; Matsuoka L; Du L; Gandhi RT; Collins ZS; Matrana MR; Petroziello M; Brower JS; Sze DY; Kennedy AS; Golzarian J; Wang EA; Brown DB
    BMC Gastroenterol; 2022 Nov; 22(1):467. PubMed ID: 36396989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma.
    Gordon AC; Gabr A; Riaz A; Uddin OM; Abouchaleh N; Ali R; Kallini J; Salem R; Lewandowski RJ
    Cardiovasc Intervent Radiol; 2018 Oct; 41(10):1557-1565. PubMed ID: 29948005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma.
    Lee YB; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim HC; Paeng JC; Yoon JH; Kim YJ
    Clin Cancer Res; 2023 Sep; 29(18):3650-3658. PubMed ID: 37459133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?
    Zu Q; Schenning RC; Jahangiri Y; Tomozawa Y; Kolbeck KJ; Kaufman JA; Al-Hakim R; Naugler WE; Nabavizadeh N; Kardosh A; Billingsley KG; Mayo SC; Orloff SL; Enestvedt KK; Maynard E; Ahn J; Lhewa D; Farsad K
    Cardiovasc Intervent Radiol; 2020 May; 43(5):721-731. PubMed ID: 32140840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization.
    Xing M; Kokabi N; Camacho JC; Kim HS
    BMC Cancer; 2018 Jan; 18(1):75. PubMed ID: 29329568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
    Yu S; Yu M; Keane B; Mauro DM; Helft PR; Harris WP; Sanoff HK; Johnson MS; O'Neil B; McRee AJ; Somasundaram A
    Oncologist; 2024 Mar; 29(3):270-e413. PubMed ID: 38325328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.
    Gabr A; Abouchaleh N; Ali R; Vouche M; Atassi R; Memon K; Asadi AA; Baker T; Caicedo JC; Desai K; Fryer J; Hickey R; Abeccassis M; Habib A; Hohlastos E; Ganger D; Kulik L; Lewandowski RJ; Riaz A; Salem R
    Eur J Radiol; 2017 Aug; 93():100-106. PubMed ID: 28668402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection.
    Ali R; Riaz A; Gabr A; Abouchaleh N; Mora R; Al Asadi A; Caicedo JC; Abecassis M; Katariya N; Maddur H; Kulik L; Lewandowski RJ; Salem R
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2195-2202. PubMed ID: 28812136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.
    Salem R; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Ibrahim S; Atassi B; Baker T; Gates V; Miller FH; Sato KT; Wang E; Gupta R; Benson AB; Newman SB; Omary RA; Abecassis M; Kulik L
    Gastroenterology; 2010 Jan; 138(1):52-64. PubMed ID: 19766639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Albumin-bilirubin grade as a prognostic indicator for patients with non-hepatocellular primary and metastatic liver malignancy undergoing Yttrium-90 radioembolization using resin microspheres.
    Azar A; Devcic Z; Paz-Fumagalli R; Vidal LLC; McKinney JM; Frey G; Lewis AR; Ritchie C; Starr JS; Mody K; Toskich B
    J Gastrointest Oncol; 2020 Aug; 11(4):715-723. PubMed ID: 32953155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis.
    Floridi C; Pesapane F; Angileri SA; De Palma D; Fontana F; Caspani F; Barile A; Del Sole A; Masciocchi C; Lucignani G; Carrafiello G
    Med Oncol; 2017 Sep; 34(10):174. PubMed ID: 28875374
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
    Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
    Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
    Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
    Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
    Vouche M; Lewandowski RJ; Atassi R; Memon K; Gates VL; Ryu RK; Gaba RC; Mulcahy MF; Baker T; Sato K; Hickey R; Ganger D; Riaz A; Fryer J; Caicedo JC; Abecassis M; Kulik L; Salem R
    J Hepatol; 2013 Nov; 59(5):1029-36. PubMed ID: 23811303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Gordon AC; Gupta AN; Gabr A; Thornburg BG; Kulik LM; Ganger DR; Maddur H; Flamm SL; Boike JR; Moore CM; Borja-Cacho D; Christopher DA; Katariya NN; Ladner DP; Caicedo-Ramirez JC; Riaz A; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2021 Feb; 32(2):211-219. PubMed ID: 33349507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.
    Gabr A; Kulik L; Mouli S; Riaz A; Ali R; Desai K; Mora RA; Ganger D; Maddur H; Flamm S; Boike J; Moore C; Thornburg B; Alasadi A; Baker T; Borja-Cacho D; Katariya N; Ladner DP; Caicedo JC; Lewandowski RJ; Salem R
    Hepatology; 2021 Mar; 73(3):998-1010. PubMed ID: 32416631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.